Ofloxacin CAS:82419-36-1

Ofloxacin is indicated for the treatment of bacterial infections caused by susceptible pathogens in adults and children. It is commonly used to manage respiratory tract infections, such as pneumonia, bronchitis, and sinusitis, due to its activity against common respiratory pathogens like Haemophilus influenzae and Moraxella catarrhalis. In urinary tract infections, ofloxacin demonstrates effectiveness against uropathogens like Escherichia coli, Proteus species, and Enterococcus faecalis. For skin and soft tissue infections, ofloxacin's ability to penetrate tissues and achieve high concentrations at the site of infection makes it a suitable choice for treating cellulitis, abscesses, and wound infections. Topical formulations of ofloxacin are utilized for eye and ear infections, including bacterial conjunctivitis and otitis externa, providing local antibacterial therapy with minimal systemic exposure. Adverse effects associated with ofloxacin therapy include gastrointestinal disturbances, central nervous system side effects, and musculoskeletal issues, such as tendon rupture. Patients should be monitored for signs of adverse reactions and advised to report any unexpected symptoms promptly. Due to the potential risk of developing antibiotic resistance, the appropriate use of ofloxacin based on susceptibility testing and guideline recommendations is crucial to ensure optimal patient outcomes and minimize the emergence of resistant bacterial strains. Collaborating with healthcare providers to determine the most suitable treatment approach and monitoring response to therapy are essential for successful management of bacterial infections with ofloxacin.